Xenon’s seizure drug study reads out soon. Here’s what to expect
admin The legacy of Richard Pops is inextricably linked to the evolution of the CNS market....
Health
Sarepta CEO Doug Ingram will retire after a tumultuous decade
Ingram’s exit is not merely a corporate transition; it is a deeply personal pivot. During...
FDA Rejection of Atara’s Rare Cancer Therapy Sparks Controversy Amid Allegations of Leadership Shift and Internal Reversal.
The experimental therapy for a rare blood cancer was on a seemingly clear path toward...
Pharma and Biotech Industries Mount Vigorous Defense Against Trump Administration’s International Reference Pricing Models for Medicare
The pharmaceutical and biotechnology sectors are intensifying their opposition to a pair of aggressive Trump...
Bayer sues J&J over ‘false and misleading claims’ about competing prostate cancer treatments
At the heart of the dispute are promotional materials and public statements issued by J&J...
Gilead to buy Arcellx in nearly $8B deal
The acquisition marks the culmination of a highly successful three-year courtship between the two firms....
The Silent Epidemic: How ‘The Pitt’ and Real-World Advocacy are Exposing the Staggering Crisis of American Medical Debt.
In a recent and harrowing episode of the HBO Max medical drama "The Pitt," a...
ACIP meeting postponed, for reasons that are unclear
The reality of this "nicotine wellness" boom is far more complex and medically precarious. While...
FDA’s New Drug Chief Signals Scrutiny of Antidepressants and RSV Shots While Roche Plans Exit from Key Antibiotic Production.
The landscape of American pharmaceutical regulation and the global supply chain for essential medicines are...
Element Biosciences launches table-top sequencer capable of $100 genome
The most significant tremor in the oncology sector involves Grail’s Galleri blood test, a multi-cancer...
